1.5284
0.55%
0.0084
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AXDX Giù?
Forum
Previsione
Frazionamento azionario
Accelerate Diagnostics Inc Borsa (AXDX) Ultime notizie
North America Antibiotic Sensitivity Testing Market By Application - Third Eye News
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine - Business Wire
Chlamydia Infection Diagnostics And Therapeutics Global Market 2024Latest Trends, Technological Advancem... - WhaTech
Blood Culture Tests Market 2024: Pioneering Innovations in Diagnostic Healthcare As Discussed In New Market... - WhaTech Technology and Markets News
New Release of Ibex Medical Analytics AI-powered Platform to Accelerate Advancements in Cancer Diagnostics - Business Wire
In Vitro Diagnostics Market Trends 2024-2033: Overview, Share, Demand, and Outlook - WhaTech
New Release of Ibex Medical Analytics AI-powered Platform to Accelerate Advancements in Cancer Diagnostics - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Emerging Trends and Opportunities in the Antimicrobial Susceptibility Testing Market - openPR
Accelerate Diagnostics regains Nasdaq compliance - Investing.com
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Defense World
Sepsis Diagnostics Market to Surge at 8.5% CAGR Through 2032Market.us Media - Market.us Media - United States Market News
Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results - Longview News-Journal
Accelerate Diagnostics Inc [AXDX] Insider Mertz Larry Michael sells 361 Shares - Knox Daily
Accelerate Diagnostics (AXDX) Completes WAVE Pre-Clinical Trial - Yahoo Finance Australia
Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns - Yahoo Finance
Earnings call: Accelerate Diagnostics Q2 2024 results and Wave program update - Investing.com
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2024 Earnings Call Transcript - Insider Monkey
Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript - Seeking Alpha
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results - Kilgore News Herald
AXDX Stock Earnings: Accelerate Diagnostics Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Accelerate Diagnostics: Q2 Earnings Snapshot - CTPost
Accelerate Diagnostics: Q2 Earnings Snapshot - Houston Chronicle
Accelerate Diagnostics: Q2 Earnings Snapshot - San Antonio Express-News
Accelerate Diagnostics: Q2 Earnings Snapshot - New Haven Register
Accelerate Diagnostics: Q2 Earnings Snapshot - Milford Mirror
Accelerate Diagnostics: Q2 Earnings Snapshot - San Francisco Chronicle
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance Australia
Accelerate Diagnostics: Q2 Earnings Snapshot - The Advocate
Accelerate Diagnostics: Q2 Earnings Snapshot - Danbury News Times
Accelerate Diagnostics reports success in WAVE trial - Investing.com
Accelerate Diagnostics reports success in WAVE trial By Investing.com - Investing.com UK
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results - StockTitan
Accelerate Diagnostics Reports Second Quarter 2024 Financial Results - PR Newswire
Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial - PR Newswire
Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results - Longview News-Journal
ACEL Stock Touches 52-Week High at $12.07 Amid Market Optimism - Investing.com Canada
ACEL Stock Touches 52-Week High at $12.07 Amid Market Optimism - Investing.com
Spear Bio secures $45 million in oversubscribed Series A financing to accelerate product launch for protein research and disease diagnostics - News-Medical.Net
Spear Bio Secures $45 Million in Oversubscribed Series A Financing to Accelerate Product Launch for Protein Research and Disease Diagnostics - Business Wire
Accelerate Diagnostics (NASDAQ:AXDX) Shares Pass Below Two Hundred Day Moving Average of $1.23 - Defense World
Antimicrobial Resistance Surveillance Market Size to Hit - GlobeNewswire
Antimicrobial Resistance Surveillance Market Size to Hit US$ 9.50 Billion by 2032, Rising Prevalence of Drug-Resistant Infections Drives Growth | Research by SNS Insider - India Shorts
Sapio Sciences Launches Partner Program to Accelerate Research and Diagnostics - Yahoo Finance
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation - MSN
Antibiotic Sensitivity Testing Market Size 2024 Research Report - WICZ
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation - Morningstar
Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation - The Malaysian Reserve
Accelerate Diagnostics (NASDAQ:AXDX) Shares Cross Above Fifty Day Moving Average of $1.14 - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
Covid-19 Diagnostic Industry Research Study |Abbott Diagnostics, Accelerate Diagnostics, Ador Diagnostics ... - economica.ma
Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) 38% Jump Shows Its Popularity With Investors - Yahoo New Zealand News
Chemiluminescence Immunoassay (CLIA) Analyzers Market Global Analysis Projected to Reach USD 9.7 Billion by - EIN News
Short Interest in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Rises By 30.0% - Defense World
ARK Innovation ETF (NYSEARCA:ARKK) Shares Sold by SteelPeak Wealth LLC - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo New Zealand News
Antibiotic Sensitivity Testing Market May Set New Growth Story - openPR
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline - Yahoo Singapore News
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):